Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML

Inclusion Criteria: * Clinical and laboratory diagnosis of CBF-AML,including RUNX1-RUNX1T1 and CBF-MYH11 fusion gene rearrangement by PCR/FISH * In status of complete remission after one to two courses of induction therapy * Total bilirubinic acid ≤ 35μmol/L, AST/ALT\<2 times abnormal level, serum creatinine \< 1.5mg/ml * Cardiac function: EF ≥ 50% * Hydroxyurea can be used for patient with white blood cell count ≥ 50\*109/L * ECOG (Eastern Cooperative Oncology Group) score: ≤ 2 Exclusion Criteria: * Relapsed/refractory AML * Serious liver/ kidney dysfunction * Cardiac function level: 2 above * Female in pregnancy or lactation * With serious infection diseases or other diseases * Not obey the principle of clinical study